Rapport Therapeutics (RAPP) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
10 Jun, 2026Opening remarks and agenda
The meeting was called to order by the CEO, with legal counsel recording the minutes and confirmation that the meeting was held in accordance with bylaws and Delaware law.
Stockholders were welcomed, and the agenda was limited to official business as described in the notice and proxy statement.
Directors, executive team, and representatives from the audit firm and legal counsel were introduced.
Rules of conduct and voting eligibility were explained, with instructions for submitting questions and voting through the virtual platform.
Board and executive committee updates
Three nominees for Class 2 directors were presented for election to serve a three-year term, with no additional nominations received.
The board unanimously recommended voting in favor of the director nominees.
Corporate governance
An independent inspector of elections was appointed to oversee and tabulate voting results.
The audit committee, composed entirely of independent directors, appointed the audit firm for the coming fiscal year.
Stockholder ratification of the audit firm was sought as a matter of good governance, though not required by bylaws.
Latest events from Rapport Therapeutics
- RAP-219 shows robust efficacy in drug-resistant epilepsy, advancing to Phase 3 with strong financial backing.RAPP
Corporate presentation - Net loss widened to $76.5M despite $20M in new licensing revenue; cash runway extends into 2029.RAPP
Q2 2026 - RAP-219 delivers robust efficacy in drug-resistant epilepsy, advancing toward major market opportunities.RAPP
Corporate presentation - Phase 2A epilepsy data for RAP-219 expected Q3 2024, with pipeline and cash runway through 2026.RAPP
TD Cowen 45th Annual Healthcare Conference - Lead program demonstrates robust efficacy in epilepsy, with phase 3 trials and expansion planned.RAPP
Stifel 2025 Healthcare Conference - RAP-219's pivotal epilepsy and bipolar trials advance with robust funding and global reach.RAPP
Stifel 2026 Virtual CNS Forum - Global phase III epilepsy trials advance with robust data and broad commercial potential.RAPP
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - RAP-219 shows strong efficacy in epilepsy, with phase III and LAI programs advancing.RAPP
Jefferies Global Healthcare Conference 2026 - 77.8% median seizure reduction and 24% seizure freedom achieved, supporting Phase 3 trials.RAPP
Study Result